A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate

Recruiting

99 years or below

All

Phase 3

8 participants needed

1 Location

Brief description of study

this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to end of the 4-week double-blind treatment phase (Day 28).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: depression, treatment resistant depression, TRD
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 844402

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants with Treatment-resistant Depression

Brief description of study

Eligibility of study

Find a site

Interested in the study